Loading…
Thursday, December 18, 2014
Current Weather
Loading Current Weather....
HomeNewsMedical
Published: Saturday, 4/5/2014 - Updated: 8 months ago

About 400 attend 17th annual Parkinson's Disease Symposium in Maumee

BLADE STAFF
Dr. Brian Fiske, vice president of research programs for The Michael J. Fox Foundation for Parkinson’s Research, speaks during the 17th annual Parkinson’s Disease Symposium today at the Parkway Place in Maumee. Dr. Brian Fiske, vice president of research programs for The Michael J. Fox Foundation for Parkinson’s Research, speaks during the 17th annual Parkinson’s Disease Symposium today at the Parkway Place in Maumee.
THE BLADE/LORI KING Enlarge | Buy This Photo

About 400 people came to Parkway Place in Maumee today for an update on the latest research of ways to treat those diagnosed with Parkinson Disease.

Highlights of the 17th annual Parkinson's Disease Symposium themed "Today's Research, Tomorrow's Hope," featured  a 60-minute keynote presentation by Dr. Brian Fiske, vice president of research programs for The Michael J. Fox Foundation for Parkinson’s Research.

Topics covered by Dr. Friske included developments in Parkinson treatment research, new treatments, and new clinical research studies available.

“The treatment of Parkinson’s disease is quite individualized, so it is extremely important for patients to keep up-to-date with the latest research and treatment options to meet our goal of making this disease as insignificant as possible in their lives,” said Dr. Lawrence Elmer, professor of neurology and director of the Gardner-McMaster Parkinson Center at The University of Toledo, in a prepared statement.

 



Guidelines: Please keep your comments smart and civil. Don't attack other readers personally, and keep your language decent. If a comment violates these standards or our privacy statement or visitor's agreement, click the "X" in the upper right corner of the comment box to report abuse. To post comments, you must be a Facebook member. To find out more, please visit the FAQ.

Related stories